The AlphaLISA® PD-1/PD-L1 Binding Kit is designed for the detection of binding activity between Human PD-1 and PD-L1, using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of therapeutics which competitively inhibit PD-1/PD-L1 interaction.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Part Number||Unit Size||List Price||Your Price||Quantity|
|AL356HV||100 assay points||436.00 GBP|
|AL356C||500 assay points||926.00 GBP|
|AL356F||5,000 assay points||6110.00 GBP|
You successfully added item(s) to your cart
This kit is designed for the detection of binding activity between PD-1 and PD-L1 using a homogeneous AlphaLISA® assay (no wash steps). This assay can facilitate the design and development of therapetics by using competitive binding.
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated PD-1 binds to the Streptavidin-coated Alpha Donor beads, while His tagged PD-L1 is captured by Anti-His AlphaLISA Acceptor beads. When PD-L1 binding to PD-1 happens, Dono. beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Programmed death ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and is expressed in tumor cells. PD-L1 binds to its receptor, PD-1, found on activated T cells, B cells, and myeloid cells, to modulate activation or inhibition. By binding to PD-1, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression and thus contribute to cancer growth. Monoclonal antibodies targeting PD-1 and PD-L are being developed as a means to boost the immune system for the treatment of non-small-cell lung cancer, melanoma, bladder, renal, and triple-negative breast cancers.
Disclaimer: For research use only. Not for use in diagnostic procedures.
|Assay Target||PD-1, PD-L1|
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 assay points|
|Resource Type||File Name||File Format|
|Brochure||Alpha product listing||PDF 124 KB|
|Application Note||Screening for Inhibitors of PD-1 and PD-L1 Binding with AlphaLISA Technology||PDF 1 MB|
|Application Note||Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint||PDF 1 MB|
|Event||Society of Laboratory Automation & Screening (SLAS)||Event|